Calidi Biotherapeutics Raises $1.2M in Registered Direct Offering — Calidi Biotherapeutics, Inc.

Event summary

Calidi Biotherapeutics raised $1.2M through a registered direct offering of 1,025,640 shares at $1.17 per share.
Closing expected on or about September 18, 2026, subject to customary conditions.
Proceeds to be used for working capital and general corporate purposes.
Offering conducted under a shelf registration statement on Form S-3, effective since October 10, 2024.

The big picture

Calidi Biotherapeutics' $1.2M registered direct offering reflects the ongoing need for biotech companies to secure non-dilutive financing to support clinical development. The deal underscores the strategic importance of Calidi's RedTail platform in targeting metastatic cancers, a space with significant unmet medical need. The offering's success will be closely watched as an indicator of investor confidence in the company's ability to execute on its pipeline.

What we're watching

Execution Risk: How Calidi will deploy the $1.2M to advance its pipeline, particularly CLD-401, which is in IND-enabling studies.
Market Dynamics: Whether the registered direct offering will stabilize Calidi's stock price, which has been trading at $1.17 per share.
Regulatory Headwinds: The pace at which Calidi can navigate regulatory approvals for its therapeutic candidates, given the high unmet medical need in its target indications.